The corticospinal tract in huntington's disease

Cerebral Cortex

Volumn 25, Issue 9, 2015, Pages 2670-2682

  Phillips, O ^a   Squitieri, F ^c   Sanchez Castaneda, C ^b   Elifani, F ^c   Griguoli, A ^c   Maglione, V ^c   Caltagirone, C ^a,d   Sabatini, U ^b   Di Paola, M ^a,e  

^a Clinical and Behavioural Neurology Department   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

CAG repeats; Corticospinal tract; DTI diffusion tensor imaging; Huntington's disease; Structural connectivity; Tractography

Indexed keywords

ADULT; AGE; ARTICLE; BRAIN STEM; CAG REPEAT; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PYRAMIDAL TRACT; ANALYSIS OF VARIANCE; IMAGE PROCESSING; MIDDLE AGED; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SPINAL CORD; STATISTICS;

ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR CORTEX; PYRAMIDAL TRACTS; SPINAL CORD; STATISTICS AS TOPIC;

EID: 84965184936     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhu065     Document Type: Article

References (123)

1. Alexander DC, Pierpaoli C, Basser PJ, Gee JC. 2001. Spatial transformations of diffusion tensor magnetic resonance images. IEEE Trans Med Imaging. 20:1131-1139.
2. Ashburner J, Friston KJ. 2000. Voxel-based morphometry-the methods. NeuroImage. 11:805-821.
3. Aylward E, Mills J, Liu D, Nopoulos P, Ross CA, Pierson R, Paulsen JS. 2011. Association between age and striatal volume stratified by cag repeat length in prodromal huntington disease. PLoS Curr. 3: RRN1235.
4. Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, Feeney J, Davis A, Rosenblatt A, Pearlson GD et al. 1998. Frontal lobe volume in patients with Huntington's disease. Neurology. 50:252-258.
5. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS. 2012. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry. 71:822-828.
6. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS. 2011. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 82:405-410.
7. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J. 1999. Increased basal ganglia iron levels in Huntington disease. Arch Neurology. 56:569-574.
8. Bartzokis G, Lu PH, Heydari P, Couvrette A, Lee GJ, Kalashyan G, Freeman F, Grinstead JW, Villablanca P, Finn JP et al. 2012. Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry. 72:1026-1034.
9. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, Finn JP, Huang D, Bordelon Y, Mintz J, Perlman S. 2007. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res. 32:1655-1664.
10. Bartzokis G, Tishler TA. 2000. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol. 46:821-833.
11. Beenen N, Buttner U, Lange HW. 1986. The diagnostic value of eye movement recordings in patients with Huntington's disease and their offspring. Electroencephalogr Clin Neurophysiol. 63:119-127.
12. Beglinger LJ, Nopoulos PC, Jorge RE, Langbehn DR, Mikos AE, Moser DJ, Duff K, Robinson RG, Paulsen JS. 2005. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol. 18:102-107.
13. Benton A, Hamsher K. 1978. Multilingual aphasia examination manual. Iowa City: University of Iowa.
14. Blekher T, Johnson SA, Marshall J, White K, Hui S, Weaver M, Gray J, Yee R, Stout JC, Beristain X et al. 2006. Saccades in presymptomatic and early stages of Huntington disease. Neurology. 67:394-399.
15. Bohanna I, Georgiou-Karistianis N, Egan GF. 2011. Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiol Dis. 42:475-481.
16. Bohanna I, Georgiou-Karistianis N, Sritharan A, Asadi H, Johnston L, Churchyard A, Egan G. 2011. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 5:171-180.
17. Bruyn GW, von Wolferen WJ 1973. Pathogenesis of Huntington's chorea. Lancet. 1:1382.
18. Catani M, Howard RJ, Pajevic S, Jones DK. 2002. Virtual in vivo interactive dissection of white matter fasciculi in the human brain. NeuroImage. 17:77-94.
19. Catani M, Jones DK, Donato R, Ffytche DH. 2003. Occipito-temporal connections in the human brain. Brain. 126:2093-2107.
20. Cherubini A, Peran P, Caltagirone C, Sabatini U, Spalletta G. 2009. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. NeuroImage. 48:29-36.
21. Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH. 2013. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PloS one. 8:e77023.
22. ∗ relaxometry and diffusion tensor imaging. Magn Reson Med. 61:1066-1072.
23. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F. 2006. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med. 47:215-222.
24. Concha L, Gross DW, Wheatley BM, Beaulieu C. 2006. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. NeuroImage. 32:1090-1099.
25. Conturo TE, Lori NF, Cull TS, Akbudak E, Snyder AZ, Shimony JS, McKinstry RC, Burton H, Raichle ME. 1999. Tracking neuronal fiber pathways in the living human brain. Proc Natl Acad Sci USA. 96:10422-10427.
26. Dale AM, Fischl B, Sereno MI. 1999. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage. 9:179-194.
27. Dale AM, Sereno MI. 1993. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: a linear approach. J Cogn Neurosci. 5:162-176.
28. Deichmann R, Schwarzbauer C, Turner R. 2004. Optimisation of the 3D MDEFT sequence for anatomical brain imaging: technical implications at 1.5 and 3T. NeuroImage. 21:757-767.
29. de la Monte SM, Vonsattel JP, Richardson EP Jr 1988. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol. 47:516-525.
30. Della Nave R, Ginestroni A, Tessa C, Giannelli M, Piacentini S, Filippi M, Mascalchi M. 2010. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am J Neuroradiol. 31:1675-1681.
31. Di Paola M, Luders E, Cherubini A, Sanchez-Castaneda C, Thompson PM, Toga AW, Caltagirone C, Orobello S, Elifani F, Squitieri F et al. 2012. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb Cortex. 22:2858-2866.
32. Di Paola M, Luders E, Di Iulio F, Cherubini A, Passafiume D, Thompson PM, Caltagirone C, Toga AW, Spalletta G. 2010. Callosal atrophy in mild cognitive impairment and Alzheimer's disease: different effects in different stages. NeuroImage. 49:141-149.
33. Di Paola M, Phillips OR, Sanchez-Castaneda C, Di Pardo A, Maglione V, Caltagirone C, Sabatini U, Squitieri F. Reduced iron content in Hungtinton Disease corpus callosum Hum Brain Mapp, accepted.
34. Douaud G, Behrens TE, Poupon C, Cointepas Y, Jbabdi S, Gaura V, Golestani N, Krystkowiak P, Verny C, Damier P et al. 2009. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage. 46:958-966.
35. Douaud G, Jbabdi S, Behrens TE, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, Kindlmann G, Matthews PM et al. 2011. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. NeuroImage. 55:880-890.
36. Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B, Alzheimer's Disease Neuroimaging Initiative. 2013. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease. PLoS Comput Biol. 9:e1002987.
37. Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA et al. 2012. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum Brain Mapp. 33:203-212.
38. Ehrlich ME 2012. Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics. 9:270-284.
39. Esmaeilzadeh M, Ciarmiello A, Squitieri F. 2011. Seeking brain biomarkers for preventive therapy in Huntington disease. CNS Neurosci Ther. 17:368-386.
40. Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy GM, Gamst AC, Hamilton JM, Salmon DP, Jernigan TL. 2004. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology. 63:989-995.
41. Fischl B, Dale AM. 2000. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 97:11050-11055.
42. Fischl B, Liu A, Dale AM. 2001. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 20:70-80.
43. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S et al. 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 33:341-355.
44. Fischl B, Salat DH, van der Kouwe AJ, Makris N, Segonne F, Quinn BT, Dale AM. 2004. Sequence-independent segmentation of magnetic resonance images. NeuroImage. 23(SUPPL. 1):S69-S84.
45. Fischl B, Sereno MI, Dale AM. 1999. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. NeuroImage. 9:195-207.
46. Fischl B, Sereno MI, Tootell RB, Dale AM. 1999. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 8:272-284.
47. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D et al. 2004. Automatically parcellating the human cerebral cortex. Cereb Cortex. 14:11-22.
48. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:189-198.
49. Folstein SE 1989. Huntington's disease: a disorder of families. Baltimore: John Hopkins University Press.
50. Gaser C, Franke K, Kloppel S, Koutsouleris N, Sauer H, Alzheimer's Disease Neuroimaging Initiative. 2013. Brain AGE in mild cognitive impaired patients: predicting the conversion to Alzheimer's disease. PloS One. 8:e67346.
51. Golding CV, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C. 2006. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology. 67:485-487.
52. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP et al. 2001. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 49:29-34.
53. Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E. 1998. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol. 154:663-672.
54. Han I, You Y, Kordower JH, Brady ST, Morfini GA. 2010. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem. 113:1073-1091.
55. Hasan KM, Sankar A, Halphen C, Kramer LA, Brandt ME, Juranek J, Cirino PT, Fletcher JM, Papanicolaou AC, Ewing-Cobbs L. 2007. Development and organization of the human brain tissue compartments across the lifespan using diffusion tensor imaging. Neuroreport. 18:1735-1739.
56. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME. 2000. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet. 9:2789-2797.
57. Jech R, Klempir J, Vymazal J, Zidovska J, Klempirova O, Ruzicka E, Roth J. 2007. Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord. 22:1783-1789.
58. Jellison BJ, Field AS, Medow J, Lazar M, Salamat MS, Alexander AL. 2004. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol. 25:356-369.
59. Jomova K, Valko M. 2011. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des. 17:3460-3473.
60. Jones DK, Knosche TR, Turner R. 2013. White matter integrity, fiber count, and other fallacies: The do's and don'ts of diffusion MRI. NeuroImage. 73:239-254.
61. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J et al. 2006. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. NeuroImage. 30:436-443.
62. Kandel ER, Schwartz JH, Jessell TM. 2000. Principles of neural science, 5th ed. New York: McGraw-Hill.
63. Kieburtz K, Penney JB, Como P, Ranen N, Shoulson I, Feigin A, Abwender D, Greenamyre JT, Higgins D, Marshall FJ et al. 1996. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord. 11:136-142.
64. Kloppel S, Draganski B, Golding CV, Chu C, Nagy Z, Cook PA, Hicks SL, Kennard C, Alexander DC, Parker GJ et al. 2008. White matter connections reflect changes in voluntary-guided saccades in presymptomatic Huntington's disease. Brain. 131:196-204.
65. Kochunov P, Glahn DC, Lancaster J, Thompson PM, Kochunov V, Rogers B, Fox P, Blangero J, Williamson DE. 2011. Fractional anisotropy of cerebral white matter and thickness of cortical gray matter across the lifespan. NeuroImage. 58:41-49.
66. Konrad A, Winterer G. 2008. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr Bull. 34:72-92.
67. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, Fazekas F, Ropele S. 2010. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257:455-462.
68. Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. 2008. Microstructural maturation of the human brain from childhood to adulthood. NeuroImage. 40:1044-1055.
69. Magnotta VA, Kim J, Koscik T, Beglinger LJ, Espinso D, Langbehn D, Nopoulo P, Paulsen JS. 2009. Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging Behav. 3:77-84.
70. Mascalchi M, Lolli F, Della Nave R, Tessa C, Petralli R, Gavazzi C, Politi LS, Macucci M, Filippi M, Piacentini S. 2004. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology. 232:867-873.
71. Matsui JT, Vaidya JG, Johnson HJ, Magnotta VA, Long JD, Mills JA, Lowe MJ, Sakaie KE, Rao SM, Smith MM et al. 2014. Diffusion weighted imaging of prefrontal cortex in prodromal huntington's disease. Hum Brain Mapp. 35:1562-1573.
72. Muhlau M, Gaser C, Wohlschlager AM, Weindl A, Stadtler M, Valet M, Zimmer C, Kassubek J, Peinemann A. 2007. Striatal gray matter loss in Huntington's disease is leftward biased. Movement disorders: official journal of the Movement Disorder Society 22:1169-1173.
73. Muller HP, Glauche V, Novak MJ, Nguyen-Thanh T, Unrath A, Lahiri N, Read J, Say MJ, Tabrizi SJ, Kassubek J et al. 2011. Stability of white matter changes related to Huntington's disease in the presence of imaging noise: a DTI study. PLoS Curr. 3:RRN1232.
74. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP Jr, Bird ED. 1991. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol. 50:729-742.
75. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS, Group P-HICoHS. 2010. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 40:544-554.
76. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC. 2006. Brain structure in preclinical Huntington's disease. Biol Psychiatry. 59:57-63.
77. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D et al. Coordinators of the Huntington's Study G. 2010. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 82:201-207.
78. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. 1997. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 41:689-692.
79. Peran P, Cherubini A, Luccichenti G, Hagberg G, Demonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U. 2009. Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp. 30:2667-2675.
80. Persichetti F, Carlee L, Faber PW, McNeil SM, Ambrose CM, Srinidhi J, Anderson M, Barnes GT, Gusella JF, MacDonald ME. 1996. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis. 3:183-190.
81. Phillips O, Sanchez-Castaneda C, Elifani F, Maglione V, Di Pardo A, Caltagirone C, Squitieri F, Sabatini U, Di Paola M. 2013. Tractography of the corpus callosum in Huntington's disease. PLoS One. 8: e73280.
82. Phillips OR, Clark KA, Luders E, Azhir R, Joshi SH, Woods RP, Mazziotta JC, Toga AW, Narr KL. 2013. Superficial white matter: effects of age, sex, and hemisphere. Brain Connectivity. 3:146-159.
83. Phillips OR, Nuechterlein KH, Asarnow RF, Clark KA, Cabeen R, Yang Y, Woods RP, Toga AW, Narr KL. 2011. Mapping corticocortical structural integrity in schizophrenia and effects of genetic liability. Biol Psychiatry. 70:680-689.
84. Phillips OR, Nuechterlein KH, Clark KA, Hamilton LS, Asarnow RF, Hageman NS, Toga AW, Narr KL. 2009. Fiber tractography reveals disruption of temporal lobe white matter tracts in schizophrenia. Schizophr Res. 107:30-38.
85. Pierpaoli C, Barnett A, Pajevic S, Chen R, Penix LR, Virta A, Basser P. 2001. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. NeuroImage. 13:1174-1185.
86. Puig J, Blasco G, Daunis IEJ, Thomalla G, Castellanos M, Figueras J, Remollo S, van Eendenburg C, Sanchez-Gonzalez J, Serena J et al. 2013. Decreased corticospinal tract fractional anisotropy predicts long-term motor outcome after stroke. Stroke; a journal of cerebral circulation. 44:2016-2018.
87. Reading SA, Yassa MA, Bakker A, Dziorny AC, Gourley LM, Yallapragada V, Rosenblatt A, Margolis RL, Aylward EH, Brandt J et al. 2005. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 140:55-62.
88. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N et al. 2003. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 60:1615-1620.
89. Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH et al. 2010. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical 'disconnection'. NeuroImage. 49: 2995-3004.
90. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. 2008. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 131:1057-1068.
91. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH. 2006. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord. 21:1317-1325.
92. Rowe KC, Paulsen JS, Langbehn DR, Duff K, Beglinger LJ, Wang C, O'Rourke JJ, Stout JC, Moser DJ. 2010. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychol. 24:435-442.
93. Sanchez-Castaneda C, Cherubini A, Elifani F, Peran P, Orobello S, Capelli G, Sabatini U, Squitieri F. 2013. Seeking huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp. 34:1625-1635.
94. Schmierer K, Wheeler-Kingshott CA, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, Scaravilli F, Barker GJ, Tofts PS, Miller DH. 2008. Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med. 59:268-277.
95. Schultz SK 2001. Principles of neural science, 4th ed. Am J Psychiatry. 158:662-662.
96. Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, Fischl B. 2004. A hybrid approach to the skull stripping problem in MRI. NeuroImage. 22:1060-1075.
97. Smith A. 1973. Symbol digit modalities test manual. Los Angeles: Western Psychological Services.
98. Smith SM 2002. Fast robust automated brain extraction. Hum Brain Mapp. 17:143-155.
99. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. 2002. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. NeuroImage. 17:1429-1436.
100. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. 1991. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology. 41:1117-1123.
101. Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, Ciammola A, Colonnese C, Frati L, Ciarmiello A. 2009. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther. 15:1-11.
102. Sritharan A, Egan GF, Johnston L, Horne M, Bradshaw JL, Bohanna I, Asadi H, Cunnington R, Churchyard AJ, Chua P et al. 2010. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry. 81:257-262.
103. Steen RG, Reddick WE, Ogg RJ. 2000. More than meets the eye: significant regional heterogeneity in human cortical T1. Magn Reson Imaging 18:361-368.
104. Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR. 2010. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology. 74:1208-1216.
105. Stroop JR 1935. Studies of interference in serial verbal reactions [Ph. D.]. Nashville, Tenn.: George Peabody College for Teachers. 19 p.
106. Supprian T, Hofmann E, Warmuth-Metz M, Franzek E, Becker T. 1997. MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects. Psychiatry research 75:173-182.
107. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI et al. 2009. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8:791-801.
108. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL et al. 2012. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11:42-53.
109. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL et al. 2011. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10:31-42.
110. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H et al. 2013. Predictors of phenotypic progression and disease onset in premanifest and earlystage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 12:637-649.
111. Takahashi M, Ono J, Harada K, Maeda M, Hackney DB. 2000. Diffusional anisotropy in cranial nerves with maturation: quantitative evaluation with diffusion MR imaging in rats. Radiology. 216:881-885.
112. Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS. 2002. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain. 125:1815-1828.
113. Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, ten Donkelaar HJ, Kremer B. 2005. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol. 109:321-328.
114. Wakana S, Caprihan A, Panzenboeck MM, Fallon JH, Perry M, Gollub RL, Hua K, Zhang J, Jiang H, Dubey P et al. 2007. Reproducibility of quantitative tractography methods applied to cerebral white matter. NeuroImage. 36:630-644.
115. Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S. 2004. Fiber tract-based atlas of human white matter anatomy. Radiology. 230:77-87.
116. Wedeen VJ, Wang RP, Schmahmann JD, Benner T, Tseng WY, Dai G, Pandya DN, Hagmann P, D'Arceuil H, de Crespigny AJ 2008. Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers. NeuroImage. 41:1267-1277.
117. Wheeler-Kingshott CA, Cercignani M. 2009. About "axial" and "radial" diffusivities. Magn Reson Med. 61:1255-1260.
118. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, Duan W, Reeves SA et al. 2011. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J Neurosci. 31:9544-9553.
119. Xu X, Wang Q, Zhang M. 2008. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. NeuroImage 40:35-42.
120. Yablonskiy DA, Haacke EM. 1994. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn ResonMed. 32:749-763.
121. Youdim MB, Stephenson G, Ben Shachar D. 2004. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Annals of the New York Academy of Sciences 1012:306-325.
122. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H et al. 1986. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 36:244-249.
123. Zuccato C, Cattaneo E. 2007. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 81:294-330.